Translate Bio

Translate Bio is focused on pioneering the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases. The company’s RNA platforms for powering endogenous therapeutic protein production is applicable to a broad range of diseases caused by insufficient protein production, including rare diseases of the liver, lung and central nervous system (CNS). Translate Bio went public in June 2018 (NASDAQ: TBIO). 

Headquarters Cambridge, MA
Twitter @TranslateBio​
Pipeline Clinical